Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
02 Maio 2024 - 8:00AM
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical
stage biotechnology company developing innovative therapeutics for
fibro-inflammatory diseases with high unmet need, today announced
that Chief Executive Officer Dr. Adi Mor will deliver a corporate
presentation at the
Aegis Virtual Conference on
May 7, 2024 at 9:00 am ET. Dr. Mor’s presentation will be webcast
live. The registration link to access the live presentation is
included below and is also available at the Events section of the
Chemomab website.
Chemomab Presentation at 2024 Aegis Virtual
Conference
Date: |
May 7, 2024 |
Time: |
9:00 am ET |
Venue: |
Virtual |
Format: |
Live webcast presentation |
Registration: |
https://us02web.zoom.us/meeting/register/tZMkd-2trzIsHNTrU4RNyTw2dYX2Pqs_t-o8 |
Information: |
info@aegiscap.com |
|
|
About Chemomab Therapeutics
Ltd.Chemomab is a clinical stage biotechnology company
developing innovative therapeutics for fibro-inflammatory diseases
with high unmet need. Based on the unique and pivotal role of CCL24
in promoting fibrosis and inflammation, Chemomab developed CM-101,
a monoclonal antibody that neutralizes CCL24 activity. In clinical
and preclinical studies, CM-101 appears safe, with the potential to
treat multiple severe and life-threatening fibro-inflammatory
diseases. Chemomab has reported positive results from three
clinical trials of CM-101 in patients, including a Phase 2a liver
fibrosis trial in NASH patients and an investigator-initiated study
in patients with severe lung injury. A Phase 2 trial in primary
sclerosing cholangitis has completed patient enrollment, with
topline data expected midyear 2024. Chemomab’s CM-101 program for
the treatment of systemic sclerosis is Phase 2-ready with an open
U.S. IND. For more information about Chemomab, visit
chemomab.com.
Contacts:
Media and Investors:Barbara
LindheimConsulting Vice President, Investor & Public Relations,
Strategic CommunicationsPhone: +1
917-355-9234barbara.lindheim@chemomab.comIR@chemomab.com
Chemomab Therapeutics (NASDAQ:CMMB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Chemomab Therapeutics (NASDAQ:CMMB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024